Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline

Insulet outlined growth plans around Omnipod 5 expansion, a next-generation Omnipod 6 platform, and a fully closed-loop system for type 2 diabetes.

• Reported 2025 revenue of USD 2.7 billion, more than 600,000 active customers, and presence in 26 global markets.
• Targets U.S. type 1 diabetes penetration of 50%-55% by 2028 from about 40% today; targets U.S. type 2 diabetes penetration of 10%-15% from about 5%.
• Pipeline milestones include Omnipod 6 clinical study results with a 510(k) filing, then launch; type 2 fully closed-loop pivotal study start, 510(k) filing, then launch.
• Highlighted 2021-2025 financial trajectory, including adjusted operating margin rising to 17.6% and free cash flow of USD 378 million in 2025.